Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 20 September 2019. Eran Atlas.

Executive Summary

Tel-Aviv, Isreal-based DreaMed Diabetes received another US Food and Drug Administration clearance for its AI-powered Advisor Pro software, which helps providers manage and optimize treatment for patients with type 1 diabetes. See what DreaMed's CEO, Eran Atlas, said about it here.

"What we have right now with our technology is the ability to provide recommendations for the entire insulin pump type 1 population, so we are more than doubling the market potential for our business." – Eran Atlas, CEO, DreaMed Diabetes

Click here for a free trial of Medtech Insight

Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT125654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel